rilvegostomig
1 product
4 abstracts
Abstract
GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.Org: Chang Gung Memorial Hospital at Linkou and Chang Gung University, Seoul National University Graduate School, AstraZeneca Global R&D (China) Co., AstraZeneca Pharmaceutical Co.,
Abstract
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.Org: Mayo Clinic Comprehensive Cancer Center, IRCCS San Raffaele Hospital, UCL Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study.Org: NeoGenomics Ltd,
Abstract
GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers.Org: NTUH Cancer Hospital, B2F Samsung Comprehensive Cancer Center, Jiangsu, China, Shatin, Hong Kong,
Product
AZD2936